Reissig Kathrin, Silver Andrew, Hartig Roland, Schinlauer Antje, Walluscheck Diana, Guenther Thomas, Siedentopf Sandra, Ross Jochen, Vo Diep-Khanh, Roessner Albert, Poehlmann-Nitsche Angela
Department of Pathology, Otto-von-Guericke University, Magdeburg, Germany.
Colorectal Cancer Genetics, Centre for Genomic and Child Health, Blizard Institute, Barts and The London School of Medicine and Dentistry, London, UK.
Oxid Med Cell Longev. 2017;2017:9303158. doi: 10.1155/2017/9303158. Epub 2017 Jun 7.
Dysregulation of c-Jun -terminal kinase (JNK) activation promoted DNA damage response bypass and tumorigenesis in our model of hydrogen peroxide-associated ulcerative colitis (UC) and in patients with quiescent UC (QUC), UC-related dysplasia, and UC-related carcinoma (UC-CRC), thereby adapting to oxidative stress. In the UC model, we have observed features of oncogenic transformation: increased proliferation, undetected DNA damage, and apoptosis resistance. Here, we show that Chk1 was downregulated but activated in the acute and quiescent chronic phases. In both phases, Chk1 was linked to DNA damage response bypass by suppressing JNK activation following oxidative stress, promoting cell cycle progression despite DNA damage. Simultaneously, activated Chk1 was bound to chromatin. This triggered histone acetylation and the binding of histone acetyltransferases and transcription factors to chromatin. Thus, chromatin-immobilized activated Chk1 executed a dual function by suppressing DNA damage response and simultaneously inducing chromatin modulation. This caused undetected DNA damage and increased cellular proliferation through failure to transmit the appropriate DNA damage signal. Findings in vitro were corroborated by chromatin accumulation of activated Chk1, Ac-H3, Ac-H4, and c-Jun in active UC (AUC) in vivo. Targeting chromatin-bound Chk1, GCN5, PCAF, and p300/CBP could be a novel therapeutic strategy to prevent UC-related tumor progression.
在我们的过氧化氢相关性溃疡性结肠炎(UC)模型以及静止期UC(QUC)、UC相关发育异常和UC相关癌(UC-CRC)患者中,c-Jun末端激酶(JNK)激活失调促进了DNA损伤反应旁路和肿瘤发生,从而适应氧化应激。在UC模型中,我们观察到了致癌转化的特征:增殖增加、未检测到DNA损伤以及抗凋亡。在此,我们表明Chk1在急性和静止期慢性阶段表达下调但被激活。在这两个阶段,Chk1通过在氧化应激后抑制JNK激活与DNA损伤反应旁路相关联,尽管存在DNA损伤仍促进细胞周期进程。同时,激活的Chk1与染色质结合。这引发了组蛋白乙酰化以及组蛋白乙酰转移酶和转录因子与染色质的结合。因此,固定在染色质上的激活的Chk1通过抑制DNA损伤反应并同时诱导染色质调节发挥双重功能。这导致未检测到DNA损伤,并通过未能传递适当的DNA损伤信号而增加细胞增殖。体外研究结果在体内活动性UC(AUC)中激活的Chk1、Ac-H3、Ac-H4和c-Jun的染色质积累得到了证实。靶向与染色质结合的Chk1、GCN5、PCAF和p300/CBP可能是预防UC相关肿瘤进展的一种新的治疗策略。